XNASNYXH
Market cap274mUSD
Dec 23, Last price
8.00USD
1D
-0.12%
1Q
-4.99%
IPO
-73.43%
Name
Nyxoah SA
Chart & Performance
P/E
—
P/S
60.76
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.00%
Rev. gr., 5y
%
Revenues
4m
+40.99%
Net income
-43m
L+38.39%
CFO
-45m
L+55.72%
Earnings
Jan 07, 2025
Profile
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 4,348 40.99% | 3,084 261.97% | 852 1,134.78% | ||||
Cost of revenue | 49,957 | 35,866 | 17,368 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (45,609) | (32,782) | (16,516) | ||||
NOPBT Margin | |||||||
Operating Taxes | (1,445) | 1,169 | 2,980 | ||||
Tax Rate | |||||||
NOPAT | (44,164) | (33,951) | (19,496) | ||||
Net income | (43,212) 38.39% | (31,225) 13.06% | (27,619) 125.55% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 18,337 | 255 | 77,728 | ||||
BB yield | -14.13% | -0.20% | -14.20% | ||||
| Debt | |||||||
Debt current | 1,215 | 1,107 | 1,136 | ||||
Long-term debt | 15,456 | 14,080 | 13,858 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 203 | 59 | 92 | ||||
Net debt | (41,077) | (79,842) | (120,679) | ||||
| Cash flow | |||||||
Cash from operating activities | (44,778) | (28,756) | (25,336) | ||||
CAPEX | (2,500) | (16,349) | (11,817) | ||||
Cash from investing activities | 32,011 | (89,946) | (11,817) | ||||
Cash from financing activities | 16,858 | (983) | 76,472 | ||||
FCF | (46,521) | (34,332) | (20,737) | ||||
| Balance | |||||||
Cash | 57,748 | 94,856 | 135,509 | ||||
Long term investments | 173 | 164 | |||||
Excess cash | 57,531 | 94,875 | 135,630 | ||||
Stockholders' equity | (155,766) | (113,596) | (82,538) | ||||
Invested Capital | 266,695 | 242,207 | 240,119 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 27,968 | 25,819 | 23,793 | ||||
Price | 4.64 -7.01% | 4.99 -78.30% | 23.00 | ||||
Market cap | 129,772 0.73% | 128,838 -76.46% | 547,232 | ||||
EV | 88,695 | 48,996 | 426,553 | ||||
EBITDA | (43,249) | (30,850) | (14,854) | ||||
EV/EBITDA | |||||||
Interest | 1,207 | 4,320 | 2,072 | ||||
Interest/NOPBT | |||||||